Detalles de la búsqueda
1.
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.
Cell
; 172(4): 825-840.e18, 2018 02 08.
Artículo
Inglés
| MEDLINE | ID: mdl-29336888
2.
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.
Mol Carcinog
; 2024 May 02.
Artículo
Inglés
| MEDLINE | ID: mdl-38695604
3.
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.
Invest New Drugs
; 41(2): 284-295, 2023 04.
Artículo
Inglés
| MEDLINE | ID: mdl-36867316
4.
Bromodomain inhibitors a decade later: a promise unfulfilled?
Br J Cancer
; 123(12): 1713-1714, 2020 12.
Artículo
Inglés
| MEDLINE | ID: mdl-32989227
5.
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
Br J Cancer
; 123(11): 1590-1598, 2020 11.
Artículo
Inglés
| MEDLINE | ID: mdl-32913286
6.
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
Breast Cancer Res Treat
; 184(1): 53-62, 2020 Nov.
Artículo
Inglés
| MEDLINE | ID: mdl-32803633
7.
A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas.
Br J Cancer
; 121(2): 131-138, 2019 07.
Artículo
Inglés
| MEDLINE | ID: mdl-31217479
8.
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.
Br J Cancer
; 119(12): 1471-1476, 2018 12.
Artículo
Inglés
| MEDLINE | ID: mdl-30425349
9.
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
Br J Cancer
; 117(9): 1258-1268, 2017 Oct 24.
Artículo
Inglés
| MEDLINE | ID: mdl-28859059
10.
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.
Invest New Drugs
; 35(5): 616-626, 2017 10.
Artículo
Inglés
| MEDLINE | ID: mdl-28194539
11.
Pharmacokinetic study of aldoxorubicin in patients with solid tumors.
Invest New Drugs
; 33(2): 341-8, 2015 Apr.
Artículo
Inglés
| MEDLINE | ID: mdl-25388939
12.
A multicenter, open-label, Phase 1 study evaluating the safety and tolerability of pegaspargase in combination with gemcitabine in advanced metastatic solid tumors and lymphoma.
Cancer Invest
; 33(5): 172-9, 2015 May.
Artículo
Inglés
| MEDLINE | ID: mdl-25844818
13.
Adnectin-targeted inhibitors: rationale and results.
Curr Oncol Rep
; 17(8): 35, 2015 Aug.
Artículo
Inglés
| MEDLINE | ID: mdl-26045129
14.
Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
Int J Clin Pharmacol Ther
; 53(7): 563-72, 2015 Jul.
Artículo
Inglés
| MEDLINE | ID: mdl-26073352
15.
Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors.
Invest New Drugs
; 32(6): 1236-45, 2014 Dec.
Artículo
Inglés
| MEDLINE | ID: mdl-25117475
16.
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.
Nat Med
; 2024 Jun 01.
Artículo
Inglés
| MEDLINE | ID: mdl-38824244
17.
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 10(3): 362-371, 2024 Mar 01.
Artículo
Inglés
| MEDLINE | ID: mdl-38236590
18.
Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer.
Cancer Cell
; 42(1): 70-84.e8, 2024 01 08.
Artículo
Inglés
| MEDLINE | ID: mdl-38194915
19.
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
J Clin Oncol
; 42(11): 1288-1300, 2024 Apr 10.
Artículo
Inglés
| MEDLINE | ID: mdl-38301187
20.
A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors.
Invest New Drugs
; 31(4): 974-85, 2013 Aug.
Artículo
Inglés
| MEDLINE | ID: mdl-23377661